KRT19 and neoplasm: Following the criterion, we identified KRT19 is highly expressed in NSCLC but not normal tissues, targeting of which not only induces NSCLC cell senescence, but also enhances the function of tumor-infiltrating CTLs and synergistically represses NSCLC progression when combining with anti-PD-1.